Corvus Pharmaceuticals, Inc.
|Number of Estimates|
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
Market Cap: 94.4 Million
Primary Exchange: NASDAQ
Shares Outstanding: 29.4 Million
Float: 21.1 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Short Interest (Jan 12, 2018): 1.02 Million
Longest drawdown: 945 trading days
From: 2017-03-27 To: 2019-11-12
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|